97 related articles for article (PubMed ID: 27776468)
1. The cost of warfarin treatment for stroke prevention in patients with non-valvular atrial fibrillation in Mexico from a collective perspective.
Briere JB; Bowrin K; Wood R; Holbrook T; Roberts J
J Med Econ; 2017 Mar; 20(3):266-272. PubMed ID: 27776468
[TBL] [Abstract][Full Text] [Related]
2. The cost of warfarin treatment for stroke prevention in patients with non-valvular atrial fibrillation in Russia from a collective perspective.
Briere JB; Bowrin K; Wood R; Roberts J; Tatarsky B
J Med Econ; 2017 Jun; 20(6):599-605. PubMed ID: 28151036
[TBL] [Abstract][Full Text] [Related]
3. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
[TBL] [Abstract][Full Text] [Related]
4. Real-life cost of vitamin K antagonist treatment in patients with non-valvular atrial fibrillation in France in 2013.
Dallongeville J; Ansolabehere X; Karusisi N; Maurel F; Van Ganse E; Le Heuzey JY
J Med Econ; 2017 Sep; 20(9):974-981. PubMed ID: 28682153
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses.
Li X; Tse VC; Lau WC; Cheung BM; Lip GY; Wong IC; Chan EW
PLoS One; 2016; 11(6):e0157129. PubMed ID: 27362421
[TBL] [Abstract][Full Text] [Related]
6. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
[TBL] [Abstract][Full Text] [Related]
7. Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
Amin A; Stokes M; Makenbaeva D; Wiederkehr D; Wu N; Lawrence JH
J Med Econ; 2014 Nov; 17(11):771-81. PubMed ID: 25133458
[TBL] [Abstract][Full Text] [Related]
8. Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation.
Amin A; Stokes M; Wu N; Gatt E; Makenbaeva D; Wiederkehr D; Boulanger L
J Med Econ; 2013 Oct; 16(10):1193-202. PubMed ID: 23883416
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
[TBL] [Abstract][Full Text] [Related]
10. Out-of-range international normalized ratio values and healthcare cost among new warfarin patients with non-valvular atrial fibrillation.
Nelson WW; Wang L; Baser O; Damaraju CV; Schein JR
J Med Econ; 2015 May; 18(5):333-40. PubMed ID: 25549062
[TBL] [Abstract][Full Text] [Related]
11. Budget impact analysis of rivaroxaban vs. warfarin anticoagulation strategy for direct current cardioversion in non-valvular atrial fibrillation patients: the MonaldiVert Economic Study.
Russo V; Rago A; Papa AA; Bianchi V; Tavoletta V; DE Vivo S; Cavallaro C; Nigro G; D'Onofrio A
Minerva Cardioangiol; 2018 Feb; 66(1):1-5. PubMed ID: 28948752
[TBL] [Abstract][Full Text] [Related]
12. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan.
Hori M; Ikeda S; Okumura K; Matsuda S; Koretsune Y; Montouchet C; Watanabe-Fujinuma E; Evers T; Rossi B; Ruff L; Briere JB
J Med Econ; 2016 Sep; 19(9):889-99. PubMed ID: 27112188
[TBL] [Abstract][Full Text] [Related]
14. The hidden costs of anticoagulation in hospitalized patients with non-valvular atrial fibrillation.
Burnett A; Tiongson J; Downey R; Mahan CE
Expert Opin Pharmacother; 2013 Jun; 14(9):1119-33. PubMed ID: 23574619
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.
Hohnloser SH; Cappato R; Ezekowitz MD; Evers T; Sahin K; Kirchhof P; Meng IL; van Eickels M; Camm AJ;
Europace; 2016 Feb; 18(2):184-90. PubMed ID: 26487668
[TBL] [Abstract][Full Text] [Related]
16. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
Ali A; Bailey C; Abdelhafiz AH
Age Ageing; 2012 Sep; 41(5):681-4. PubMed ID: 22378612
[TBL] [Abstract][Full Text] [Related]
17. The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation.
Amorosi SL; Armstrong S; Da Deppo L; Garfield S; Stein K
Europace; 2014 Aug; 16(8):1131-6. PubMed ID: 24687964
[TBL] [Abstract][Full Text] [Related]
18. Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation.
Mercaldi CJ; Ciarametaro M; Hahn B; Chalissery G; Reynolds MW; Sander SD; Samsa GP; Matchar DB
Stroke; 2011 Jan; 42(1):112-8. PubMed ID: 21148442
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients.
Nguyen E; Egri F; Mearns ES; White CM; Coleman CI
Pharmacotherapy; 2016 May; 36(5):488-95. PubMed ID: 27015873
[TBL] [Abstract][Full Text] [Related]
20. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.
Martinez C; Katholing A; Wallenhorst C; Freedman SB
Thromb Haemost; 2016 Jan; 115(1):31-9. PubMed ID: 26246112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
